卵巢癌,联合疗法 z-bo 2020-10-08 261

　　Researchers at the University Hospital Research Center of Montreal (CRCHUM) have developed a two-step combination therapy to destroy cancer cells. Research published in the journal Nature Communications shows that based on the control of cellular aging, this "combined punch" has a better therapeutic effect on patients with ovarian cancer.

　　With the passage of time, our cells will age and enter a stage called cell aging. These senescent cells stop growing and accumulate in the body, leading to the development of cancer and other diseases. In recent years, the scientific community has tried to treat these aging-related diseases by targeting and destroying senescent cells.

　　"Epithelial ovarian cancer (EOC) is the most common and deadly ovarian cancer. It uses a two-step method for treatment. First, it ages cancer cells prematurely. This is the first time. Treatment. Then use photodegradation technology for the second Attack to destroy and eliminate. This strategy requires two steps to be properly coordinated. A Francis Rodier said.

　　The research team led by Odier and his colleague Anne Marie Mes-Masson found that EOC cells enter a state of senescence after being treated with PARP inhibitors and chemotherapy. PARP is an enzyme that helps repair DNA damage. PARP inhibitors can prevent cancer cells from repairing DNA by blocking PARP, prevent cancer cell growth, and may cause cancer cells to age prematurely.

　　"We have successfully used the "combined punch" method to destroy aging EOC cells in preclinical ovarian cancer models. Our method can improve the effectiveness of PARP inhibitors combined with chemotherapy and counteract the systemic effects of this treatment resistance. "Said Mes-Masson, a professor at the University of Montreal and a researcher at CRCHUM.

　　"The cells used in our study were taken from samples from patients with ovarian cancer. These patients participated in the study and agreed to save their biological samples. The "comprehensive drilling strategy" was also implemented in preclinical ovarian and breast cancer models. This method It has been tested and its effectiveness can be verified. The results of this study will be used in clinical trials for ovarian cancer and triple-negative breast cancer, but Rodier said it is important to remember that he is using a clinical trial without an immune system The former model. Yes, "Given the importance of the human immune response, we need to continue to evaluate our strategies in a context closer to biological reality. "